A secondary endpoint from this study demonstrated that patients taking VESIcare experienced a statistically significant increase in warning time compared with patients taking placebo. VESIcare is the first overactive bladder (OAB) treatment at an approved dose to show a statistically significant increase in warning time.
“Urgency is generally considered to be the most important symptom for patients suffering from OAB,” said Marc Toglia, Urogynecology Associates of Philadelphia. “Increasing the time interval between the first sensation to void and the act of voiding may be an important goal as it could reduce the likelihood of a patient experiencing an incontinent episode.”
Overactive bladder affects an estimated 17 million men and women in the US. It is estimated that costs related to OAB were nearly $14 billion in the US in 2000, similar to that of gynecological and breast cancers, osteoporosis, or arthritis.